Document is current

Article History

Received: 16 November 2024

Accepted: 27 March 2025

First Online: 15 April 2025

Competing interests

: LAH: AdBoard: Pfizer, AstraZeneca. Research funding to institution: Greenwich LifeSciences. Book royalties: McGraw Hill. RM: Consultant/advisor: Agendia, Arvinas, Astra Zeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, Sanofi, Sermonix, Stemline. Research support (paid to institution): Gilead. SF: No disclosures. ND: Consulting: Gilead, Novartis, Lilly, Pfizer, MJH Life Sciences, PrecisCa, Neogenomics. SP: No disclosures. AR: Employment at Bristol Myers Squibb. SJ: No disclosures. LQ: No disclosures. MM: For Myself: Research funding to institution: Pfizer, KCRN Research, Puma, OBI Pharma. For spouse: Speaker bureau/honoraria: Gilead, Astra Zeneca/Daichi-sankyo; Stock Ownership: Merrimack. JC: Research funding to institution: Merck, Puma, Amgen, Seagen, Pfizer, Olema. Ad board: Genentech. AS: Adboard: Merck, AstraZenca, Stemline, Genzyme, Gilead. LC: AdBoard/consulting: AstraZeneca/Daiichi Sankyo. MA: Consulting: Bayer, Xoft, Apollomics, Viewray, Cairn Therapeutics, AnheartTherapeutics, Theraguix, MenariniRicerche, Sumitomo Pharma Oncology, Autem therapeutics, GT Medical Technologies, Allovir, EquilliumBio., QV Bioelectronics, Servier Pharmaceuticals, Incyte. DSMC: VBI Vaccines Scientific Advisory Board: Modifibiosciences., Bugworks Shareholder: Mimivax, Cytodyn, MedInnovateAdvisors LLC, TrisalusLifesciences Funding: 1R01CA277728-01A1, 1R01 CA264017-01A1. NH: No disclosures. JH: AdBoard/consulting: AstraZeneca. AB: No COI relevent to this paper. KB: No disclosures. MK: No disclosures. DI: No disclosures. RR: Consulting/Advisory Boards: AstraZeneca, DSI, Ter-sera, Lilly, Genentech, Lilly, Pfizer, Merck. KG: Advisory board with honoraria to institution for Astra Zeneca, Novartis, Puma Biotechnologies, Eli Lilly, Gilead, Exact Sciences, Neogenomics and Tersera Therapeutics. HR: Institutional research support: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Stemline Therapeutics, OBI Pharma; Ambryx. Consultancy/advisory: Chugai, Puma, Napo.